Watch as Barry T. Katzen, MD, FACR, FACC, FSIR, president and founding board member of the Critical Limb Ischemia Global Society, discusses why you should join the Society. 

Watch as Dr. Barry Katzen, president and founding board member of the CLI Global Society, discusses the importance of membership in the Society.

Watch as Barry Katzen, MD, provides an update on what's new with the CLI Global Society and the Journal of Critical Limb Ischemia.

Since there was a striking paucity of high-level comparative effectiveness evidence on the optimal treatment of patients with CLTI so far, both these landmark trials were awaited with great interest. However, study outcomes are conflicting and therefore worthy of intensive review and in-depth analysis for all medical professions confronted with such patients.

Barry Katzen interviews 10 experts on CLTI who each bring their varied specialties, experiences, and opinions to help us understand the BEST-CLI trial results. Study design analysis, generalizability, and real-world application are some of the topics discussed.

The initial results of the long-awaited BEST-CLI (Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia) trial were recently published in the New England Journal of Medicine. There is a lack of prospective, randomized data to guide treatment of peripheral arterial disease, and this landmark trial is worthy of review and analysis by any practitioner treating CLTI.

The current study describes the underlying rationale, objectives, and methods to explore PAD, CLI, and CKD associations.

The CLI Global Society was formed in 2016 to improve patient quality of life by preventing amputations and death due to CLI. Barry Katzen, MD, President of the CLI Global Society, discusses the society's mission and the role of the Journal of Critical Limb Ischemia in achieving its goals.